CNS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.215 USD | +5.39% |
|
+6.44% | -83.07% |
| 04-23 | Transcript : CNS Pharmaceuticals, Inc. - Special Call | |
| 04-01 | CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 6.67M 532M |
|---|---|---|---|---|---|
| Net income 2022 | -15M -1.2B | Net income 2023 | -18M -1.44B | EV / Sales 2022 | - |
| Net cash position 2022 | 9.65M 771M | Net cash position 2023 | 248K 19.8M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.21
x | P/E ratio 2023 |
-0.25
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on CNS Pharmaceuticals, Inc.
More press releases
| 1 day | +5.39% | ||
| 1 week | +6.44% | ||
| Current month | -40.61% | ||
| 1 month | -40.61% | ||
| 3 months | -48.77% | ||
| 6 months | -88.62% | ||
| Current year | -83.07% |
1 week
0.19
0.22
1 month
0.190.39
Current year
0.191.30
1 year
0.192.98
3 years
0.1980.40
5 years
0.19170.70
10 years
0.19170.70
| Managers | Title | Age | Since |
|---|---|---|---|
John Climaco
CEO | Chief Executive Officer | 55 | 31/08/17 |
| Director of Finance/CFO | 45 | 12/11/19 | |
Sandra Silberman
CTO | Chief Tech/Sci/R&D Officer | 69 | 30/11/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Picker
CTO | Chief Tech/Sci/R&D Officer | 78 | 31/12/17 |
John Climaco
CEO | Chief Executive Officer | 55 | 31/08/17 |
Faith Charles
CHM | Chairman | 62 | 02/01/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.215 | +5.39% | 109,097 |
| 25/04/24 | 0.204 | -4.67% | 105,007 |
| 24/04/24 | 0.214 | +1.90% | 78,498 |
| 23/04/24 | 0.21 | +5.47% | 147,832 |
| 22/04/24 | 0.1991 | -1.44% | 87,433 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
Calendar
04:15pm
- LSX World Congress
| 1st Jan change | Capi. | |
|---|---|---|
| -83.07% | 2.29M | |
| +1.51% | 42.75B | |
| +48.37% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CNSP Stock
